Alexander Sapir
Patrimonio netto: 719 290 $ in data 31/07/2026
Patrimonio netto: 719 290 $ in data 31/07/2026
Mr. Alexander C.
Sapir is a President, Chief Executive Officer & Director at Fulcrum Therapeutics, Inc., an Independent Director at PhaseBio Pharmaceuticals, Inc. and a Chief Executive Officer & Director at ReViral Ltd. He is on the Board of Directors at Fulcrum Therapeutics, Inc., PhaseBio Pharmaceuticals, Inc. and ReViral Ltd. Mr. Sapir was previously employed as a President, Chief Executive Officer & Director by Dova Pharmaceuticals, Inc., an Executive Vice President-Marketing & Sales by United Therapeutics Corp., and a Senior Director-Marketing by Guilford Pharmaceuticals, Inc. He received his undergraduate degree from Franklin & Marshall College and an MBA from Harvard Business School.
| Società | Data | Numero di azioni | Valutazione | Data di valutazione |
|---|---|---|---|---|
| 31/03/2026 | 200.919 ( 0,26% ) | 719 290 $ | 31/07/2026 |
| Società | Posizione | Inizio |
|---|---|---|
| PHASEBIO PHARMACEUTICALS, INC. | Direttore/Membro del Consiglio | 12/02/2020 |
| FULCRUM THERAPEUTICS, INC. | Amministratore Delegato | 01/07/2023 |
ReViral Ltd.
ReViral Ltd. BiotechnologyHealth Technology Develops novel antiviral therapeutics | Amministratore Delegato | 10/06/2019 |
| Società | Posizione | Fine |
|---|---|---|
| DOVA PHARMACEUTICALS, INC. | Amministratore Delegato | 01/12/2018 |
| UNITED THERAPEUTICS CORPORATION | Vendite & Marketing | 01/05/2016 |
Guilford Pharmaceuticals, Inc.
Guilford Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops drugs used to treat neurological diseases | Vendite & Marketing | 01/01/2005 |
Attive
Inattive
Società nel listino
Aziende private
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
| Aziende private | 8 |
|---|---|
Guilford Pharmaceuticals, Inc.
Guilford Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops drugs used to treat neurological diseases | Health Technology |
United Therapeutics Corp.
United Therapeutics Corp. BiotechnologyHealth Technology Operates as a biotechnology company that develops and commercializes products to address the unmet medical needs of patients with chronic & life-threatening conditions | Health Technology |
PhaseBio Pharmaceuticals, Inc.
PhaseBio Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Engages in development and commercialization of novel therapies for cardiovascular diseases | Health Technology |
Franklin & Marshall College
Franklin & Marshall College Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Harvard Business School
Harvard Business School Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
ReViral Ltd.
ReViral Ltd. BiotechnologyHealth Technology Develops novel antiviral therapeutics | Health Technology |
Fulcrum Therapeutics, Inc.
Fulcrum Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops medicines for patients by transforming gene regulation in disease | Health Technology |
Dova Pharmaceuticals, Inc.
Dova Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops and commercializes drugs with disorder of low blood platelet count | Health Technology |
Seleziona la tua edizione
Tutte le informazioni finanziarie adattate in base al livello nazionale